Standardization of positive controls in diagnostic immunohistochemistry: Recommendations from the international ad hoc expert committee

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 1, 2015, Pages 1-18

  Torlakovic, Emina E ^a,d   Nielsen, Søren ^e,f   Francis, Glenn ^g,h,i   Garratt, John ^b,d   Gilks, Blake ^b,d   Goldsmith, Jeffrey D ^j   Hornick, Jason L ^a,k   Hyjek, Elizabeth ^a   Ibrahim, Merdol ^l   Miller, Keith ^l   Petcu, Eugen ^g   Swanson, Paul E ^c,m   Zhou, Xiaoge ^n,o   Taylor, Clive R ^p   Vyberg, Mogens ^e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Canadian Immunohistochemistry Quality Control (CIQC)   (Canada)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f Nordic Immunohistochemical Quality Control (NordiQC)   (Denmark)

^g GRIFFITH UNIVERSITY   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ RCPA QAP Pty Ltd   (Australia)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ CAPITAL MEDICAL UNIVERSITY   (China)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

iCAPCs; Immunohistochemistry; Methodology transfer; Positive controls; Prognostic and predictive biomarkers; Standardization

Indexed keywords

CLINICAL LABORATORY; CLINICAL PRACTICE; DIAGNOSTIC IMMUNOHISTOCHEMISTRY; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TASK PERFORMANCE; VALIDATION STUDY; ADVISORY COMMITTEE; EXPERT WITNESS; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; PROCEDURES; STANDARD; STANDARDS;

ADVISORY COMMITTEES; EXPERT TESTIMONY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; PRACTICE GUIDELINES AS TOPIC; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 84917730270     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000163     Document Type: Review

References (57)

1. Elias JM. Immunohistochemical methods. In: Elias JM, ed. Immunohistopathology: A Practical Approach to Diagnosis. 2nd ed. Chicago, IL: ASCP Press; 2003:1-110.
2. Taylor CR, Shi S-R, Barr NJ, et al. Techniques of immunohistochemistry: principles, pitfalls, and standardization. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 4th ed. Philadelphia, PA: Churchill Livingstone Saunders Elsevier; 2014:1-55.
3. Taylor CR, Cote RJ. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologists. 3rd ed. Philadelphia, PA: Saunders; 2005: 26-28.
4. Gavrielides MA, Conway C, O'Flaherty N, et al. Observer performance in the use of digital and optical microscopy for the interpretation of tissue-based biomarkers. Anal Cell Pathol (Amst). 2014. [Epub ahead of print].
5. O'Leary TJ. Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol. 2001;9:3-8.
6. National Committee for Clinical Laboratory Standards. Quality Assurance for Immunocytochemistry; Approved Guideline. NCCLS Document MM4-AC. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
7. Clinical and Laboratory Standards Institute. Quality Assurance for Design Control and Implementation of Immnohistochemistry Assays; Approved Guideline. 2nd ed. Wayne PA: CLSI CLSI document I/LA28-A2; 2003.
8. Ramos-Vara JA, Kiupel M, Baszler T, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. J Vet Diagn Invest. 2008;20:393-413.
9. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem. 2007;55:105-109.
10. Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med. 2000;124: 945-951.
11. Goldstein NS, Hewitt SM, Taylor CR, et al. Members of Ad-Hoc Committee on Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15:124-133.
12. Hewitt SM, Robinowitz M, Bogen SA, et al. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2011:p62-p66
13. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee. Torlakovic EE, Riddell R, Banerjee D, et al. Canadian Association of Pathologists-Association canadienne des pathologists National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol. 2010;133:354-365.
14. Shi S-R, Cote RJ, Chaiwun B, et al. Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin-fixed tissue sections. Appl Immunohistochem. 1998;6:89-96.
15. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
16. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28: 2784-2795.
17. Sato M, Kojima M, Nagatsuma AK, et al. Optimal fixation for total preanalytic phase evaluation in pathology laboratories. A comprehensive study including immunohistochemistry, DNA, and mRNA assays. Pathol Int. 2014;64:209-216.
18. Lee M, Lee CS, Tan PH. Hormone receptor expression in breast cancer: postanalytical issues. J Clin Pathol. 2013;66: 478-484.
19. Fisher KE, Cohen C, Siddiqui MT, et al. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol. 2014;S0046-8177: 00311-00316.
20. Torlakovic EE, Francis G, Garratt J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl Immunohistochem Mol Morphol. 2014;22:241-252.
21. Rhodes A, Jasani B, Couturier J, et al. A formalin-fixed, paraffinprocessed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol. 2002;117:81-89.
22. Ishikawa K, Miyamoto M, Yoshioka T, et al. Method for the validation of immunohistochemical staining using SCID mouse xenografts: expression of CD40 and CD154 in human non-small cell lung cancer. Oncol Rep. 2013;29:1315-1321.
23. Ingram M, Techy GB, Ward BR, et al. Tissue engineered tumor models. Biotech Histochem. 2010;85:213-229.
24. Kaur P, Ward B, Saha B, et al. Human breast cancer histoid: an in vitro 3-dimensional co-culture model that mimics breast cancer tissue. J Histochem Cytochem. 2011;59:1087-1100.
25. Bogen SA, Vani K, McGraw B, et al. Experimental validation of peptide immunohistochemistry controls. Appl Immunohistochem Mol Morphol. 2009;17:239-246.
26. Dunstan RW, Wharton KA Jr, Quigley C, et al. The use of immunohistochemistry for biomarker assessment - can it compete with other technologies? Toxicol Pathol. 2011;39:988-1002.
27. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/ neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953-962.
28. Dako. Hercept Test™. Interpretation Manual on Breast Cancer. Available at: http://www.dako.com/ca/28630-herceptest-interpretation-manual-breast-ihc-row.pdf. Accessed September 29, 2014.
29. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-113.
30. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35: 432-441.
31. Cheung CC, Neufeld H, Lining LA, et al. The laboratory score/ reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. Am J Clin Pathol. 2011;136:67-73.
32. Taylor CR. Predictive biomarkers and companion diagnostics. The future of immunohistochemistry - "in situ proteomics", or just a "stain"? Appl Immunohistochem Mol Morph. 2014;22:555-561.
33. Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine. Appl Immunohistochem Mol Morph. 2014;22: 1-9.
34. Torlakovic E. A S. Controls, In: Techniques, NordiQC. Available at: http://www.nordiqc.org/Techniques/Contol-sections.htm. Accessed September 29, 2014.
35. Nielsen S. Recommended control tissue. Techniques. NordiQC. Available at: http://www.nordiqc.org/Techniques/Recommended-control-tissue.htm. Accessed on January 3, 2014.
36. Arends M, Frayling IM, Happerfield L, et al. HNPCC/Lynch Syndrome Module: report of the immunohistochemical analysis of mismatch repair (MMR) protein expression. Available at: http://cmgsweb.shared.hosting.zen.co.uk/BPGs/pdfs%20current%20bpgs/hnpcc%20recommendations%20B.pdf. Accessed on September 29, 2014.
37. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol. 2014;9:1255-1263.
38. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.
39. Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol. 2001; 115:44-58.
40. Kankuri-Tammilehto MK, Sö derström KO, Pelliniemi TT, et al. Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res. 2010;30:3023-3030.
41. Agarwal M, Shenjere P, Blewitt RW, et al. CD30-positive T-cell lymphoproliferative disorder of the oral mucosa-an indolent lesion: report of 4 cases. Int J Surg Pathol. 2008;16:286-290.
42. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005;65:1406-1413.
43. NoridQC: Assessment Run 38 2013. Cytokeratin, high molecular weight (CK-HMW). Available at: http://www.nordiqc.org/Run-38/Assessment/assessment-38-CK-HMW.htm. Accessed September 29, 2014.
44. Taylor CR. Quantifiable internal reference standards for immunohistochemistry; the measurement of quantity by weight. Applied Immunohistochem Mol Morph. 2006;14:253-259.
45. Taylor CR, Levenson RM. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment. Histopathology. 2006;49:411-424.
46. Taylor CR, Becker KF. Liquid morphology: immunochemical analysis of proteins extracted from formalin fixed paraffin embedded tissues: combining proteomics with immunohistochemistry. Appl Immunohistochem Mol Morph. 2011;19: 1-9.
47. Neumeister VM, Parisi F, England AM, et al. Models and techniques. A tissue quality index; an intrinsic control for measurement of effects of pre-analytic variables on FFPE tissue. Lab Invest. 2014;94:467-474.
48. Cheung CC, Banarjee D, Barnes PJ, et al. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. AJCP. 2014;142:629-633.
49. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019. Review.
50. Cheung CC, Martin BR, Asa SL. Defining diagnostic tissue in the era of personalized medicine. CMAJ. 2013;185: 135-139.
51. Condelli V, Lettini G, Patitucci G, et al. Validation of vacuumbased refrigerated system for biobanking tissue preservation: analysis of cellular morphology, protein stability, and RNA quality. Biopreserv Biobank. 2014;12:35-45.
52. Bleuel EP, Roebers TP, Schulting E, et al. Solvent-free tissue processing using supercritical carbon dioxide. Histopathology. 2012;61:1198-1208.
53. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997-4013.
54. Dyhdalo KS, Fitzgibbons PL, Goldsmith JD, et al. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures. Arch Pathol Lab Med. 2014;138:876-884.
55. Fitzgibbons PL, Bradley LA, Fatheree LA, et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014;138:1432-1443
56. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
57. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.